MyDrHank review

What it is

A client-rendered telehealth storefront selling across longevity, weight loss, sexual health and hair. The longevity shelf is sermorelin as an injectable, NAD⁺ as both a nasal spray and a subcutaneous injection at different prices, and glutathione in the same two routes. Weight loss adds compounded semaglutide and tirzepatide plus an oral semaglutide with a compounded ondansetron anti-nausea co-formulation, which is a genuinely unusual SKU. There is no testosterone product of any kind — the "Strength" nav category resolves to sermorelin alone — which is why it does not appear on our TRT board.

How it works

Fully asynchronous telehealth with no in-person option: a three-minute questionnaire with no office visit, no insurance and no bloodwork required to start, then review by a US board-certified clinician within 24 to 48 hours depending on which page you read. Cash-pay only, with FSA and HSA claimed, cancel anytime, and no membership fee — the site is explicit that there are no membership or hidden fees and that shipping is included. Ongoing check-ins, dose adjustments and unlimited messaging are claimed. The gating is the problem: every call to action leaves the marketing site for a separate intake funnel, and nothing beyond the "from $137/mo" figure is visible before you begin — plan options, doses and the final price appear only inside the funnel. No list of states served exists anywhere, only "available in select U.S. states"; no compounding pharmacy is named, only categories; and no clinician is named at all, with the company name appearing solely as the legal entity in its privacy policy. There is no "Dr. Hank" bio anywhere on a site named after one.

Pricing transparency

The headline is not a monthly price and the monthly price is not published. "Starting at $137/month" appears on the sermorelin and NAD⁺ landers and on the NAD⁺ product modal, where it is the only dollar figure shown at all — and it is the twelve-month prepaid rate, $1,644 charged up front. The site's own served application data carries the full ladder, and it shows the real structure: sermorelin and the NAD⁺ nasal spray at $199 a month month-to-month, $169 on three months, $152 on six and $137 on twelve; the NAD⁺ injection at $225 month-to-month down to $155; glutathione at $149 down to $103. None of that ladder renders anywhere on the public site, and the product cards on the peptide and longevity pages carry no price at all. That is why both cards here publish no monthly floor: the number a visitor sees is not a month, and the number that is a month is not visible. The same pattern runs across the catalogue — the homepage's "start for just $171/mo" is the annual prepay on oral semaglutide, whose month-to-month price is $249. All of this sits alongside marketing copy promising "transparent pricing" and "flat pricing, no surprise increases".

Branded vs compounded

Compounded; not FDA-approved, and to MyDrHank's credit the disclaimer is present, prominent and correctly worded on the peptide and longevity pages, the landers and the global footer — and its weight-loss calculator correctly discloses that its data reflects FDA-approved formulations while the compounded medications it dispenses are not FDA-approved, with named trial citations. Two claims on other pages do not meet that standard. Its hair page markets products under an "FDA-approved active ingredients" banner while selling oral minoxidil, which is not FDA-approved for hair loss — only topical minoxidil is, and oral minoxidil is approved as an antihypertensive — and the same banner sits above a custom protocol of five compounded formulations that are definitionally not FDA-approved. More relevant to this board, its NAD⁺ nasal-spray product charts a "6x increase in whole blood NAD+ after 12 weeks" and cites Igarashi et al., npj Aging 2022 — a trial of oral nicotinamide mononucleotide in healthy older men. That is a different molecule delivered by a different route, and what it measured was a blood level rather than a clinical outcome. The page's own footnote concedes that clinical evidence for nasal and injectable NAD⁺ delivery is limited, which is the accurate statement, and it sits a few lines from the chart that overstates it. Sermorelin, by contrast, is positioned well: explicitly against synthetic growth hormone, on the correct mechanism, with a 1993 endocrinology citation. Individual results vary.

Pros and watch-outs

The evidence behind what MyDrHank prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

How MyDrHank compares

A few alternatives worth a look, depending on what you’re optimizing for.

• OLOak Longevity

  Low-cost sermorelin within a broader longevity stack

  See Oak Longevity →
• HEHealthRX

  Compounded sermorelin within a broad longevity and weight-care menu

  See HealthRX →
• BHBodybuilding Health+

  Pairing sermorelin with a strength-training and recovery focus

  See Bodybuilding Health+ →